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Abstract 
Major depressive disorders are common conditions with relatively limited response to 
treatment. In order to improve response to treatment, a better understanding of functional 
neuroanatomy is necessary to improve treatment targets at brain level. This work summarises 
the literature of longitudinal functional magnetic resonance imaging studies in major 
depression to identify brain regions where aberrant neural activity normalises after clinical 
response following treatment with pharmacological compounds with known antidepressant 
properties. Hyperactivity in regions such as the amygdala and the ventral components of the 
anterior cingulate cortex were some of the most replicated findings of functional MRI studies 
in major depression and normalisation of aberrant activity one of the best predictive 
biomarkers of treatment response.   
Keywords: MRI, Major depression, functional MRI, antidepressants 
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1. Introduction 
Major depressive disorders are common conditions affecting approximately 10% of the 
population (McKenna et al, 2005) likely to became second only to ischemic heart disease in 
terms of disability by 2020 (Lopez et al., 2006)(Murray and Lopez, 1997). Treatment 
modalities which include a range of psychological and pharmacological interventions, achieve 
a clinical response in the range of 50-60% of cases and remission in approximately 20-30% 
(Warden et al., 2007).  Novel research is necessary to further characterise the biological 
underpinning of depressive disorders to specifically identify brain systems to model mood 
dysregulation and offer new therapeutic targets.  Brain structure and function are the end 
product of emotional behaviours originating from environmental effects and epigenetic 
adaptations (Vanderwolf, 1998). Research in affective disorders has taken advantage of a 
range of magnetic resonance imaging (MRI) techniques to investigate mood disorders and 
response to treatment (Harmer, 2008)(Wise et al., 2014). Functional MRI techniques allow to 
study brain activity in response to neuropsychological tasks but also at rest. Affective 
cognitive neuroscience allows characterisation in vivo of brain regions involved in cognitive 
and emotional functions. In this context, experiments are designed to evaluate cognitive 
processes and assess systems reliant on the processing of emotions by eliciting emotion 
recognition or suppression (Elliott et al., 2011). This work summarises the literature of 
functional MRI studies in major depression which used a longitudinal design to identify 
clinical response following treatment with pharmacological compounds with known 
antidepressant properties.  
 
2. Methods 
The aim of the work was to select studies which identified brain regions with aberrant neural 
baseline activity that either normalised following pharmacological treatment and clinical 
response or persisted as an indicator of treatment refractoriness. Functional neuroimaging 
studies were identified by searching Medline, Embase and Scopus from the year 2000 to 
February 2018. Key words used in combination included ‘functional magnetic resonance’ or 
‘fMRI’, ‘major depression’, ‘depressive disorders’, ‘antidepressants’, ‘emotion’, ‘affective 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
neuroscience’. Identified articles were cross referenced. Functional MRI studies were included 
if 1) written in English, 2) investigated the effect of pharmacological compounds currently 
licenced to treat major depression administered to currently depressed individuals diagnosed 
according to established diagnostic systems, 3) contained matched cases and controls, 4) 
involved at least two MRI sessions before and after pharmacological treatment, 5) 
pharmacological treatment was commenced after baseline MRI scan, 6) Patients were not 
treatment resistant. Group x time interactions were reported as far as possible to minimise 
mere habituation effects.   
 
3. Results 
The searches identified over 600 reports, 93 studies were scrutinised of which 31 met 
inclusion criteria. Of these 18 used emotion processing tasks, 7 used non-emotional tasks and 
6 used resting state functional MRI techniques. The majority of the studies were excluded 
because lacked longitudinal MRI data. Reports were also excluded because individuals were 
not necessarily treatment free at the time of scanning (Keedwell et al., 2009)(Keedwell et al., 
2010), cases and controls were not matched (Andreescu et al., 2013), primarily included 
patients with dysthymia or remitted depression rather than current major depression (Posner et 
al., 2013), (Smith et al., 2017), did not include a group of healthy controls in the longitudinal 
analyses (Lisiecka et al., 2011), (Jiang et al., 2012), (Miller et al., 2013),  (Chen et al., 2007), 
(Robertson et al., 2007), (Yang et al., 2014), (Miskowiak et al., 2016a), (Miskowiak et al., 
2016b) (Ramasubbu et al., 2016), (Carhart-Harris et al., 2017), (Karim et al., 2017)(Frodl et 
al., 2011)(Samson et al., 2011), investigated adolescents (Tao et al., 2012), were superseded 
by more recent reports or data were included in other reports (Fu et al., 2008)(Light et al., 
2011)(Godlewska et al., 2012)(Wang et al., 2014a) (Wang et al., 2014b)(Fang et al., 2015), 
(Ruhé et al., 2014)(An et al., 2017)(Wang et al., 2017), used polypharmacy (Rizvi et al., 
2013), tested experimental pharmacological interventions (Furey et al., 2013)(Furey et al., 
2015), investigated treatment resistant patients (Murrough et al., 2015)(Abdallah et al., 2017), 
implemented a multivariate pattern of analysis (Qin et al., 2015), did not exclude pathology in 
controls (Aizenstein et al., 2009). 
 
3.1 Functional MRI antidepressant treatment studies with emotion processing tasks  
This group of studies investigated the effect of pharmacological treatment in major depression 
vs. healthy controls by using a range of neuropsychological tasks which triggered networks 
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implicated in the processing of emotion and emotion regulation. The large majority of this 
research utilised faces or pictures expressing graded (Young et al., 1997), validated (e.g. 
Ekman and Friesen, 1971) positive and negative emotions presented in the MRI scanner 
implicitly or explicitly, openly recognised or covertly presented to avoid suppression 
mechanisms (Elliott et al., 2011). Analyses commonly contrasted individual emotions vs. 
neutral stimuli, vs. opposite emotions or vs. baseline brain activity measured at multiple time 
points. These studies are described below and detailed in Table 1.  
Sheline and others used masked face emotions including happy, fearful and neutral to test the 
selective serotonin reuptake inhibitor (SSRI) Sertraline. Neural activity was increased in 
depression in the left amygdala at baseline which decreased after 8-week of treatment in 
response to fearful faces in bilateral amygdala (Sheline et al., 2001).  
In Davidson’s study depressed patients after viewing emotional pictures, showed reduced 
activation in left insula and left anterior cingulate cortex with negative vs. neutral contrast 
which increased after 2 weeks of treatment with the serotonin and noradrenalin reuptake 
inhibitor (SNRI) Venlafaxine. Changes in the anterior cingulate cortex were predictive of 
treatment response at week 8 (Davidson et al., 2003).  
Fu and others investigated the effects of Fluoxetine for 8 weeks on implicit processing of 
emotional faces in two separate papers with sad and happy vs. neutral contrast. With sad faces 
increased neural activity in depression was reduced after treatment in the amygdala, ventral 
striatum, insula, caudate nucleus, thalamus, dorsal and posterior cingulate cortex, precentral 
gyrus extending to the lateral premotor cortex, postcentral gyrus, and inferior parietal lobule 
(Fu et al., 2004). With happy faces a reduced dynamic range which increased significantly 
after treatment was reported in the lingual gyri and cuneus, extending to the precuneus and 
posterior cingulate gyrus bilaterally (Fu et al., 2007).  
Schaefer and colleagues measured neural responses to viewing emotional pictures which 
showed social interaction, facial expressions and erotic pictures. Depressed subjects were 
characterised by a reduction in neural activity in response to positive social stimuli in a range 
of regions including prefrontal, temporal, parietal cortices, insula, basal ganglia and the 
hippocampus which tended to reach levels comparable to healthy controls following 22 weeks 
treatment with Venlafaxine. In case of pictures showing social interactions, the regions 
included the inferior, medial, and superior frontal gyri, superior temporal gyrus, 
supramarginal gyrus, caudate, hippocampus with additional significant clusters in the right 
ventrolateral thalamic nucleus, bilateral putamen, right middle and inferior temporal gyri, and 
posterior cingulate (Schaefer et al., 2006).  
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Anand and colleagues administered Sertraline for 6 weeks and tested participants with 
emotionally evocative pictures. Following treatment, a decrease in neural activity was noted in 
overactive predefined regions of interest including pregenual anterior cingulate cortex, medial 
thalamus, pallido-striatum, amygdala with the negative vs. neutral contrast (Anand et al., 
2007).  
Fales and others used an emotion interference task to test the effect of Escitalopram, Sertraline 
or Paroxetine for 8 weeks. When ignoring fearful faces, depressed patients showed reduced 
neural activity in the right dorsolateral prefrontal cortex whereas neural activity was increased 
in the left amygdala at baseline. Neural activity normalised after treatment in these regions 
(Fales et al., 2009). 
Victor and colleagues, investigated the effect of Sertraline for 8 weeks with a backword 
masking face emotion processing task. Masked sad vs. neutral faces at baseline elicited 
increased neural activity in the amygdala in depression which attenuated with treatment. 
Responses to masked happy vs. neutral faces increased in the same region in depression and 
inversely correlated with depression severity score (Victor et al., 2010). 
With a similar design, Arnone and others treated depressed patients with Citalopram for 8 
weeks and used an implicit face emotion processing task. Currently depressed patients showed 
increased neural activity in the amygdala with the sad vs. neutral contrast at baseline which 
normalised following treatment (Danilo Arnone et al., 2012).  
Rosenblau and colleagues tested brain responses to 8 weeks treatment with Escitalopram by 
using emotional pictures presented with a cue indicating their emotional valence (expected) or 
with random letters (unexpected). The main results indicated increased neural activity in the 
amygdala when anticipating negative pictures and greater prefrontal activation (dorsolateral 
prefrontal cortex and orbitofrontal cortex) in depression when negative pictures were 
presented with no anticipatory cues. Both effects decreased after antidepressant treatment 
(Rosenblau et al., 2012). 
Another study by Ruhé and others investigated patients treated with Paroxetine for 12 weeks 
with scans at week-6 and 12 by using an implicit face emotion processing task. At baseline 
patients showed enhanced amygdala activation in response to negative faces which decreased 
at endpoint in responders (Ruhé et al., 2012). 
Wang and others administered Fluoxetine for 8 weeks and participants were required to 
explicitly respond to emotional pictures. With positive pictures, neural activity was reduced in 
the right insula, left caudate head and left anterior cingulate cortex after antidepressant 
treatment. In response to negative pictures, following treatment, patients exhibited greater 
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activation in the right middle frontal gyrus, right inferior temporal gyrus, right precuneus and 
inferior parietal lobule (Wang et al., 2012).  
Heller and others investigated individuals exposed to positive and negative pictures randomly 
treated with Venlafaxine (N=12) or Fluoxetine (N=9) for 2 months. Following treatment, the 
largest increases in sustained activity was measured in the nucleus accumbens in response to 
positive viewing. Connectivity between the nucleus accumbens and left middle frontal gyrus, 
ventromedial prefrontal cortex and right anterior insula also increased with the same 
emotional induction (Heller et al., 2013). 
Victor and colleagues used a backward masking task to elicit neural responses to implicit 
emotional faces in patients treated with Sertraline for 8 weeks. Greater responses in 
depression to masked sad vs. happy and masked sad vs. neutral faces in the right pregenual 
anterior cingulate cortex normalised post-treatment. Greater neural activity in this region in 
response to masked sad vs. happy faces at baseline was predictive of a greater reduction in 
depression severity during the course of treatment (Victor et al., 2013). 
Fu and colleagues investigated response to the SNRI Duloxetine at weeks 1, 8 and 12 with an 
emotional Stroop and face emotion processing tasks. Only the emotional Stroop induced a 
significant increase in neural activity after treatment in the left posterior temporo-parietal 
junction involving the parahippocampal cortex as well as precuneus and posterior cingulate 
cortex during the processing of negative vs. neutral words (Fu et al., 2015). 
Williams and others measured neural responses to positive and negative emotional faces 
presented both above and below conscious discrimination. Depressed individuals were 
randomised to receive Escitalopram, Sertraline, or Venlafaxine extended release for 8 weeks. 
Responders showed a decrease in neural responses in bilateral amygdala to happiness and to 
fear and anger in the left amygdala (Williams et al., 2015).  
Delaveau and others investigated the effects of Agomelatine and participants were presented 
with pictures with equal positive, negative and neutral valence requiring self-relevant or 
general responses. By contrasting the self vs. general responses, patients on Agomelatine 
showed a significant tendency to decrease neural activity in the ventrolateral prefrontal cortex 
from baseline to week 1. After 7 weeks, increased activation was noted in the ventral anterior 
cingulate cortex and decreased in the dorsolateral prefrontal cortex (Delaveau et al., 2016).  
Godlewska and colleagues employed an implicit face emotional processing task combined 
with treatment with escitalopram for 6 weeks. After 7 days of treatment a decrease in neural 
response was noted in response to fearful vs. happy faces in the left amygdala, insula, anterior 
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and posterior cingulate cortices, bilateral supra-marginal gyri and bilateral thalamus 
(Godlewska et al., 2016). 
 
In summary the majority of the studies identified investigated pharmacological effects of 
SSRIs and/or SNRIs with the exception of Agomelatine and it is not possible to reliably 
identify a specific pattern at brain level for a pharmacological class of compounds. The 
majority of patients also responded of remitted following treatment. It follows that the 
biological characterisation of non-responders is challenging. The interval between MRI scans 
ranged from 2 to 22 weeks with a mode of 8. There were substantial methodological 
differences across the studies which limit comparability and generalisability. Tasks, 
particularly with negative emotions, especially if implicitly administered, often showed 
enhanced neural activity in the amygdala in major depression (50% of studies) and the 
anterior cingulate cortex (30% of studies). Increased neural activity was also shown in 
extended circuitry including regions such as the ventral striatum, the thalamus, the nucleus 
accumbens, dorsal parts of the cingulate cortex and the insula. There was a tendency to the 
opposite effect with positive stimuli in the amygdala and in other regions such as the insula 
and basal ganglia. Neural activity in the hippocampus and thalamus was shown to be reduced 
in some of these studies with positive emotions also. Tasks which engaged cognitive 
processes, especially those evoking an emotional response, tended to elicit increased neural 
activity in a number of cortical regions including ventromedial and orbitofrontal regions and 
decreased activity in dorsolateral and ventrolateral cortices which varied in relation to the 
intensity of the signal and sometimes in the direction depending on the task used, the emotion 
valence and the presence of a self-referential element. Tasks which triggered anticipatory cues 
appeared associated with greater prefrontal activation. The presence of an interference task 
and emotional distracters resulted in decreased neural activation in cortical and subcortical 
areas including the amygdala, except the emotional Stroop task shown to be associated with 
greater activation in posterior cingulate cortex and precuneus. Based on the information 
available, major depression is particularly associated with baseline abnormalities in neural 
activity in the amygdala and anterior cingulate cortex which tend to normalise after treatment 
and clinical response. Greater abnormalities in these regions at baseline and the degree on 
normalisation appear the best predictors of clinical response with persistence of abnormalities 
in non-responders. 
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3.2 Functional MRI antidepressant treatment studies with non-emotional tasks 
The studies described below examined neural responses in major depression before and after 
antidepressant treatment in response to non-emotional stimuli including cognitive and reward 
processes. Details of the methods adopted in the studies are described below and in Table 2. 
 
Walsh and colleagues investigated the effects of 8-week treatment with Fluoxetine on working 
memory performance by using an N-back verbal working memory task. A significant increase 
in the quadratic load response activity was reported in the left caudate and right thalamus 
following treatment (Walsh et al., 2007). 
In another study a task to judge self vs. general condition was used to test the pharmacological 
effects of SSRIs, SNRIs and tricyclics administered for 9 weeks. The study was based on the 
notion that a qualitative cognitive bias towards the self can affect medial prefrontal neural 
responses in major depression. The authors reported attenuation in neural activity in the left 
dorsolateral prefrontal cortex with the self vs. general condition in depressed patients and 
sustained greater activation of the dorsal medial frontal gyrus with the same condition after 
treatment (Lemogne et al., 2010). 
López-Solà and others investigated pain symptoms in major depression in response to 8-week 
treatment with Duloxetine by using a pain induction task. Patients showed greater baseline 
activation in bilateral insula, medial prefrontal cortex, middle temporal gyrus, frontal and 
temporal opercula, left hippocampus, ventral basal ganglia, hypothalamic region, and 
abnormal persistence of activity during stimulation in a large area involving the subgenual and 
pregenual anterior cingulate cortex and extended medial prefrontal regions. After treatment 
there was a reduction in neural activity involving a similar network and the brainstem 
including the anterior and posterior parts of the pons. Reductions in symptoms of depression 
after 1 week of treatment were significantly correlated with activation reductions in the 
pregenual anterior cingulate cortex. Reductions in somatic symptoms were significantly 
correlated with activation reductions in the right dorsolateral prefrontal cortex. Improvement 
in depressive symptoms after 8 weeks of treatment correlated with activation reductions in the 
right dorsolateral prefrontal cortex and left insulo-opercular region. Remitters had greater 
activation reductions in the pons after 8 weeks of treatment (López-Solà et al., 2010). 
Wagner and colleagues used the Stroop Color-Word test to investigate neural activity in the 
rostral anterior cingulate cortex in relation to emotional interference following a course of the 
noradrenaline reuptake inhibitor (NRI) Reboxetine or Citalopram for a period of 6 weeks. A 
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predominant reduction in the activity of the amygdala–hippocampus complex was attributed 
to Citalopram (Wagner et al., 2010).  
Stoy and others investigated neural responses to Escitalopram for 6 weeks with a monetary 
incentive delay task which targeted the ventral striatum involved in response to reward as a 
proxy of hedonic tone. Patients showed decreased ventral striatal activation during 
anticipation of gain and loss which ameliorated with treatment and was associated with self-
reported measures of severity of depression and anhedonic symptoms (Stoy et al., 2012). 
Gyurak and colleagues assessed inhibitory control by using a Go/NoGo task, selective 
attention with the oddball task and selective working memory by using the continuous 
performance task. Depressed individuals were randomised to receive Escitalopram, Sertraline, 
or Venlafaxine extended release and tested at baseline and after 8 weeks. Non-remitters 
showed hypoactivation in the dorsolateral prefrontal cortex with the inhibitory NoGo task 
(Gyurak et al., 2016). 
Sankar and colleagues treated patients with Duloxetine for 12 weeks and tested neural 
responses to verbal working memory by using the Sternberg task. Authors reported reduced 
activation in healthy participants at end point and no changes in affected individuals in the left 
middle frontal gyrus, the right middle cingulum, left inferior temporal gyrus, right superior 
temporal pole, caudate, right thalamus, and cerebellum (Sankar et al., 2017). 
 
In summary, the majority of studies used SSRIs, SNRI and NRI for 6-12 weeks in 
combination with a variety of tasks. It is not possible to establish a clearly distinctive pattern 
in relation to pharmacotherapy although citalopram was associated with reduction in neural 
activity in the amygdala–hippocampus complex in one study suggesting a preferential 
normalising effect compared to Reboxetine. The majority of patients largely responded and 
remitted following treatment so that it is difficult to ascertain a clear pattern for non-
responders. Attenuation of neural activity in the dorsolateral prefrontal cortex was reported in 
43% of the studies with a self-referential task, a pain induction task (which also evoked 
responses in a wide network including the insula) and an inhibition task (reported in non-
responders). This abnormality normalised following pharmacotherapy and clinical response. 
Other noticeable brain regions included the rostral anterior cingulate cortex where increased 
neural activity was measured with an emotion interference task and the ventral striatum where 
decreased activation was shown with a reward task. Overall neural differences in major 
depression tended to attenuate following treatment and clinical response and persistence of 
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abnormalities in the dorsolateral prefrontal cortex was associated with non-response. Change 
in neural activity in these regions did not seem to show a specific pattern predictive of 
response.  
 
3.3 Resting state analysis  
These are studies that used resting state functional connectivity methods. In the absence of 
any specific task executed in the MRI scanner, these experiments were designed to evaluate 
changes in the blood oxygen level dependent signal in brain networks or regions of interest at 
rest. Methods available in the literature include the evaluation of synchronisation of regional 
activation, measures of regional homogeneity, temporal correlations between a defined ‘a 
priory’ region of interest with other voxels in the brain, and data driven analyses. Details of 
the studies are described below and in Table 3. 
 
Anand and others treated patients with Sertraline for 6 weeks. Decreased connectivity at 
baseline between the anterior cingulate cortex and left and right medial thalamus and 
pallidostriatum increased at the end of the study (Anand et al., 2005). 
After treatment with Duloxetine for 6 weeks Lai and colleagues showed that in major 
depression regional homogeneity increased in the right superior frontal cortex but also in the 
right medial frontal cortex and decreased in the right superior temporal cortex. Changes 
mildly correlated with improvement of symptoms (Lai and Wu, 2012).  
Li et al., investigated resting state activation following 12-week treatment with Paroxetine, 
Citalopram, Venlafaxine or Duloxetine with only a subgroup of patients scanned twice 
(N=16). At baseline increased connectivity was measured in a posterior network comprising 
the bilateral precuneus and in an anterior network which included the medial prefrontal cortex. 
Following treatment only connectivity in the posterior network normalised (Li et al., 2013). 
The effect of Duloxetine was investigated in a multimodal study (Fu et al., 2015 also 
described in Section 3.1). Independent functional analyses indicated that over time 
connectivity decreased in the default mode network between right dorsolateral cortex, right 
superior frontal premotor cortex and left inferior frontal gyrus. Decreased connectivity was 
also noted in the auditory processing cortex and the primary visual and extrastriate regions. 
Connectivity increased between medial prefrontal regions, including pregenual and subgenual 
cingulate and the frontal pole, parahippocampal gyrus, angular gyrus, and middle occipital 
gyrus (Fu et al., 2015). 
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Wang and colleagues investigated Escitalopram over 8 weeks.  Functional connectivity 
strength increased in the bilateral dorsomedial prefrontal cortex at baseline, correlated with 
severity depression scores and reduced following treatment and clinical response. Functional 
connectivity strength in the bilateral hippocampus followed an inverse pattern whereby 
baseline lower functional connectivity strength subsequently increased (Wang et al., 2015).  
Resting state connectivity following treatment with Escitalopram at baseline, after 5 hours, 4 
weeks and 8 weeks was evaluated by Cheng and associates. Following acute (5H) and sub-
chronic (4W and 8W) treatment administration the signal decreased in the bilateral post-
central gyrus and left superior temporal gyrus and increased in a vast area of the prefrontal 
cortex incorporating dorsomedial and dorsolateral regions (Cheng et al., 2017). 
 
In summary, these studies investigated a range of pharmacological interventions mostly 
involving SSRIs and SNRIs for a period of 24 hours-12 weeks. It is not possible to establish a 
distinctive pattern in relation to pharmacotherapy. There was a noticeable trend suggestive of 
increased functional connectivity between frontal and limbic brain regions and decreased 
functional connectivity following treatment between medial prefrontal regions and 
dorsomedial and dorsolateral cortices overlapping with areas within the default mode network.  
These findings suggest that treatment and clinical response might contribute to improve top-
down control over emotional responses and ruminative thought patterns (Perkins et al., 2015). 
 
4. Conclusion and future directions 
This work reviewed the literature pertinent to functional MRI studies investigating changes in 
brain regions in major depression, the relationship to pharmacological treatment and clinical 
response. The large majority of the studies with a longitudinal approach used 
neuropsychological tasks to test emotional circuitry, a few investigated a range of cognitive 
functions and a small group of studies examined neural response at rest. The main obstacle in 
attempting to generalise findings across the identified studies is that design differed 
significantly, a variety of approaches were used including different tasks, the length of the 
studies and pharmacological compounds varied, and several emotions and contrasts were 
used. Further limitations include methodological differences across the studies e.g. resting 
state functional connectivity instructions, scan acquisition parameters (e.g. TR, amount of 
volumes, etc.) which are known to affect both data quality and analyses results. Furthermore, 
as studies had a longitudinal design, it is possible that task habituation occurred in emotional 
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processing studies in studies where group x time interactions were not clearly described. 
Another observation is the high rate of response and remission across the studies which limits 
our understanding of the neurobiology of treatment refractoriness and perhaps suggests the 
possibility that milder forms of major depression were selected.  
With all these limitations, functional MRI studies with emotion processing tasks tend to show 
that especially in response to negative visual stimuli, neural hyperactivity is often detected in 
prefrontal areas including ventromedial, anterior cingulate and orbitofrontal cortices whilst 
subcortical brain regions such as the amygdala and ventral striatum tend to be seemingly 
overactive with a tendency in both cases to normalisation following pharmacological 
treatment. Neural activity in the hippocampus and parahippocampal gyrus seem to be reduced 
whereas neural activity in pregenual and the most ventral components of the anterior cingulate 
cortex has been shown to be increased. The most replicated predictors of treatment response 
included the amygdala and the ventral part of the anterior cingulate cortex. These are the 
regions where greater neural activity at baseline or degree on change during treatment are 
more likely to predict treatment response following treatment. Responses elicited to positive 
stimuli appeared less preponderant in the literature in major depression supporting the notion 
of selective attending of negative (e.g. sadness, fear) over positive stimuli (e.g. happiness). 
When response to positive stimuli was elicited, neural activity in the subcortical regions and 
limbic areas appeared reduced prior to treatment, with a tendency to normalise following 
pharmacological interventions. Patterns overall were less distinctive when more complex 
tasks or explicit tasks with longer time of exposure to stimuli were used, favouring the 
involvement of cognitive processes. This is because when emotional information is presented 
subliminally, it is processed independently from attention and also rapidly, automatically and 
unconsciously (Pessoa and Adolphs, 2010). Inevitably, tasks that allow longer exposures to 
attend emotions, are likely to trigger more complex feedback systems involving cortical 
regions such as the orbitofrontal cortex and neural signals become less consistent across the 
studies (Ohman, 2005).  
Results from functional MRI studies which used tasks to test cognitive functions suggest that 
prefrontal areas tend to hypofunction under performance in major depression and reductions 
in neural activity in the dorsolateral prefrontal cortex tends to normalise following response. 
Greater neural activity in the ventral striatum at baseline which normalised following 
treatment correlated with depressive symptoms. In these groups of studies, it is not possible to 
identify specific patterns in relation to pharmacological compounds or predictors of treatment 
response. Resting state studies indicated enhanced functional connectivity following treatment 
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between frontal and limbic brain regions, possibly reflecting an increase in inhibitory top-
down control over emotional responses exercised by prefrontal cortices over key limbic 
regions involved in regulation of emotions. At the same time a reduction in connectivity 
between medial prefrontal cortex and dorsal prefrontal cortices following treatment is 
suggestive of increased baseline functional activity in major depression within the default 
mode network, in agreement with recent research findings (Wise et al., 2017a). Response to 
treatment might therefore ameliorate these abnormalities which might be reflective of 
ruminative thought patterns (Perkins et al., 2015). 
 
Finding from these studies are consistent with described biological models of depression 
which advocate the importance of the integration of information across different anatomical 
brain sectors to ensure homeostatic emotion regulation. Anatomical compartments include a  
cognitive element essential in regulating responses to emotional stimuli overtly presented and 
a viscero-motor sector mediating covert responses (Mayberg, 1997)(Mayberg, 2009)(Arnone 
et al., 2016)(Wise et al., 2014). Subcortical areas such as the thalamus and the ventral striatum 
appear functionally active in the processing of emotional information (Mayberg, 2009), 
coexisting with regulatory activity in prefrontal regions exercising cognitive control and 
conscious appraisal on any given emotional state (Adolphs, 2002) (Mayberg, 2009)(Phillips et 
al., 2003). In a depressed state an overactive ‘bottom-up’ brain circuitry characterised by over-
functional key regions such as the amygdala and the anterior cingulate cortex coexist with 
underactive ‘top-down’ cortical control which includes regions in the medial and orbital part 
of the prefrontal brain (Figure 1) (Adolphs, 2002) (Mayberg, 2009)(Phillips et al., 
2003)(Roiser et al., 2012). Overactivity in key regions within the default mode might 
contribute to explain a ruminative thought pattern (Perkins et al., 2015). The involvement of 
these regions has been extensively reported in the literature also in structural MRI studies (D 
Arnone et al., 2012) (Toby Wise et al., 2018) across mood disorders (Wise et al., 2017b). 
Pharmacotherapy and clinical response appear to contribute to achieve an equilibrium 
compatible with normalisation of baseline aberrant neural activities.  
 
In summary studies described a range of abnormalities in cortical and subcortical brain 
regions in major depression. This is in agreement with models described in this condition and 
could contribute to explain cognitive bias, abnormalities in executive and working memory 
functions described in depressive disorders and response to treatment (Mayberg, 
1997)(Phillips et al., 2003)(Roiser et al., 2012). Hyperactivity in the amygdala and the ventral 
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components of the anterior cingulate cortex are the most replicated findings of functional MRI 
studies in major depression and some of the best predictive biomarkers of treatment response.  
Future work requires standardisation of procedures and methodologies. The development of a 
central depository of standardised neuroimaging data to carry out analyses of large datasets 
could help dilute the effects of confounders by increasing validity and generalisability of the 
results. 
 
Acknowledgements 
Dr Arnone has received support from the Academy of Medical Sciences, UK (grant no. AMS-
SGCL8). 
 
Ethical statement 
Dr Arnone has received travel grants from Jansen-Cilag and Servier and sponsorship from 
Lundbeck. 
 
 
Figure 1: Schematic interpretation of the results of the neuroimaging studies in major depression based on theoretical models which suggest 
an interplay between brain regions with reduced activity (inhibitory=blue) and increased activity (yellow) resulting in cognitive and 
emotional changes (Phillips et al., 2003) (Mayberg, 1997). A: brain regions with increased neural activity. From left to right: amygdala, 
insula, medial thalamus, ventral anterior cingulate cortex, dorsolateral prefrontal cortex, orbitofrontal cortex. B: brain regions with 
decreased neural activity. From left to right: Hippocampus, dorsolateral prefrontal cortex, dorsal part of the ventromedial prefrontal cortex. 
Circles and black arrows indicate brain regions most likely to be predictive of treatment response (amygdala and ventral anterior cingulate 
cortex). 
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Table 1: Functional MRI of pharmacological treatment in major depression with emotion processing tasks  
Study Diagnosis Comorbidities fMRI Task 
 
Scanner 
(T) 
N. 
Cases/controls 
Mean age  
Analyses Results in major depression  
Sheline et 
al., 2001 
DSM IV Excluded Emotional 
Faces 
1.5T  11/11 
40 years 
Amygdale 
(ROI) 
 amygdale activation after 8-week 
treatment with Sertraline. 
Davidson 
et al., 2003 
DSM IV Dysthymia 
Specific 
phobias 
Emotional 
Pictures  
1.5T  12/5 
38 years 
WB  activation in the left Ins and left ACC 
in response to negative pictures at 
baseline in which normalised after 8-
week treatment with Venlafaxine. 
Fu et al., 
2004 
DSM IV Excluded Sad Faces  1.5T  19/19 
43 years 
WB  activation in amygdala, ventral 
striatum, Ins, caudate nucleus, thalamus, 
cingulate cortex, precentral and post 
central gyri, inferior parietal lobule, 
which normalised after a course of 8-
week treatment with Fluoxetine. 
Schaefer 
et al., 2006 
DSM IV GAD, BED 
 
Emotional 
pictures 
(social 
content) 
1.5T  9/14 
36 years 
WB  in prefrontal temporal, and parietal 
cortices, insula, basal ganglia, and 
hippocampus following treatment with 
Venlafaxine for 22 weeks. 
Anand et 
al., 2007 
DSM IV Excluded Negative 
pictures 
1.5T  12/11 
30 years 
Amygdale, 
pACC, 
mTHA, 
PS, (ROI) 
 activation in left amygdala, pACC and 
PS after 6-week treatment with 
Sertraline. 
Fu et al., 
2007 
DSM IV Excluded Happy 
faces  
1.5T  19/19 
43 years 
WB  activation in lingual gyrus, cuneus, 
precuneus and PCC after following 8-
week treatment with Fluoxetine 
Fales et 
al., 2009 
DSM IV Excluded Emotion 
interference 
task 
3T  23/18 
36 years 
 
Amygdale, 
ACC, 
DLPFC, 
amygdala 
(ROI) 
 activation in the dorsolateral prefrontal 
cortex and left amygdala which 
normalised following 8-week treatment 
with Escitalopram, Sertraline, and 
Paroxetine. 
Victor et 
al., 2010 
DSM IV Anxiety 
disorders  
Emotional 
faces 
3T  22 /25 
31years 
Amygdale 
(ROI) 
 activation in amygdale with sad faced 
and  with happy faces after 8-week 
treatment with Sertraline. 
Arnone et 
al., 2012 
DSM IV Excluded Emotional 
faces 
1.5T  38 /54 
36 years 
WB, 
amygdale 
(ROI) 
Normalisation of   neural activity in 
bilateral amygdala to sad faces following 
8-week treatment with Citalopram. 
Rosenblau 
et al., 2012 
DSM IV Excluded Emotional 
pictures 
 
1.5T  12/12 
43.5 years 
mFC, 
OFC, 
DLPFC, 
ACC, 
amygdale 
(ROI) 
 activation to negative pictures in 
DLPFC, right OFC after 8-week 
treatment with Escitalopram. 
Ruhe et 
al., 2012 
DSM IV Anxiety 
disorders 
AD, CD 
Emotional 
faces 
(implicit) 
3T  22/22 
43 years 
Amygdale 
(ROI) 
 activation in left amygdala associated 
with response to treatment after 12 
weeks treatment with Paroxetine.    
Wang et 
al., 2012 
DSM IV Excluded 
 
Emotional 
judgement 
3T  18/18 
32 years 
WB  activation in the right middle frontal 
gyrus, right inferior temporal gyrus, right 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
precuneus and inferior parietal lobule 
after treatment in response to negative 
stimuli and  activation in response to 
positive pictures in the right Ins, left  
caudate head and left ACC after 8 weeks 
treatment with Fluoxetine. 
Heller et 
al., 2013 
DSM IV Excluded 
 
Emotion 
regulation 
3T  21/14 
31 years 
NA (ROI)  activation in the NA after 8 weeks of 
treatment with Fluoxetine or Venlafaxine 
and  fronto-striatal connectivity. 
Victor et 
al., 2013 
DSM IV Anxiety 
disorders 
PTSD 
Emotional 
faces 
3T  10/10 
33 years 
WB, 
pACC 
(ROI) 
The right lateral frontal polar cortex 
showed  neural activity following 
treatment with Sertraline for 8 weeks. 
Fu et al., 
2015 
DSM IV Excluded Emotional 
Stroop 
3T  32/25 
40 years 
WB  activation in the PCC, 
parahippocampal cortex, and precuneus 
after treatment with Duloxetine. 
Williams 
et al., 2015 
DSM IV Excluded Emotional 
faces  
3T  
3T  80/34 
33 years 
Amygdala 
(ROI) 
 activation in the amygdala in 
responders to happiness, fear and anger 
after 8 weeks treatment with 
Escitalopram, Sertraline, or Venlafaxine. 
Delaveau 
et al., 2016 
DSM IV Anxiety 
disorders 
Emotional 
pictures 
 
3T  25/14 
41 years 
 
DMPFC, 
VMPFC, 
PCC, 
ACC, 
VLPFC, 
DLPFC 
(ROI) 
Agomelatine showed a significant 
tendency to decrease  activation in 
VLPFC after 1 week of Agomelatine, 
and  activation in ACC and  in 
DLPFC after 7 weeks. 
Godlewska 
et al., 2016 
DSM IV Anxiety 
disorders 
Emotional 
faces 
3T   35/29 
30 years 
WB, 
amygdale, 
ACC, Ins 
(ROI)  
Depressed subjects were treated with 
escitalopram and showed a  activation 
to fearful vs. happy faces following 7-
day Escitalopram treatment in the left  
amygdala, Ins, ACC, PCC insula, 
bilateral supra-marginal gyri and 
bilateral thalamus.  
GAD: generalised anxiety disorder; BED: binge eating disorder; AD: alcohol dependence, CD: cannabis dependence; PTSD: post -traumatic stress 
disorder; WB: whole brain; ROI: region of interest; pACC: pregenual anterior cingulate cortex; ACC: anterior cingula te cortex; mTHA: medial 
thalamus; PS: pallido striatum; DLPFC: dorsolateral prefrontal cortex; DMPFC: dorsomedial prefrontal cortex; PCC: posterior c ingulate cortex, mFC: 
medial frontal cortex; VMPFC: ventromedial prefrontal cortex; VLPFC: ventrolateral prefrontal cortex; OFC: orbitofrontal cortex; NA: nucleus 
accumbens; Ins: insule 
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Table 2: Functional MRI of pharmacological treatment in major depression with non -emotional tasks  
Study Diagnosis Comorbidities fMRI Task 
 
Scanner 
(T) 
N. 
Cases/controls 
Mean age  
Analyses Results in major depression  
Walsh et 
al., 2007 
DSM IV Excluded N-Back 
verbal 
working 
memory 
1.5T  20/20 
44 years 
WB  in activation in left  caudate and right 
thalamus after 8 weeks of Fluoxetine 
treatment. 
Lemogne 
et al., 
2010 
DSM IV Not excluded Self-
judgement 
task 
1.5T  8/8 
33 years 
ROI in 
prefrontal 
cortex 
 activation in left  DLPFC and  in 
dorsomedial frontal gyrus with the self 
vs. general condition after 9 weeks of 
treatment with SSRIs, SNRIs and 
tricyclics. 
Lopez-
Sola et al., 
2010 
DSM IV Excluded Pain 
condition 
1.5T  13/20 
45 
WB  activation in a range of cortical regions 
including ventromedial prefrontal cortex, 
subgenual and pACC, middle temporal 
gyrus, DLPFC, frontal and temporal 
opercula, Ins, left hippocampus, ventral 
basal ganglia, hypothalamus at week 1 
and similarly at week 8 following 
treatment with Duloxetine. 
Wagner 
et al., 
2010 
DSM IV Excluded Stroop 
colour-
words 
1.5T  20/20 
39 
WB   amygdala-hippocampus following 6-
week treatment with Citalopram. 
Stoy et 
al., 2012 
DSM IV Excluded Monetary 
task 
1.5T  15/15 
42 
ROI in 
ventral 
striatum 
 activation in ventral striatum following 
anticipation of loss which normalised 
after treatment with Escitalopram for 6 
weeks. 
Gyurak et 
al., 2016 
DSM IV Not excluded Go/NoGo 
task,  
Oddball 
task  
Selective 
working 
memory 
Task 
3T  80/34 
32.5 
WB  activation in the DLPFC in non-
remitters which persisted after 8-week 
treatment with Escitalopram, Sertraline, 
or Venlafaxine extended release with the 
inhibitory NoGo task.  
Sankar et 
al., 2017 
DSM IV Excluded Sternberg 
task 
3T  23/22 
40 
 
WB  activation in healthy participants over 
12 weeks and no changes in affected 
individuals treated with Duloxetine in 
the left  middle frontal gyrus, the right 
middle cingulum, left  inferior temporal 
gyrus, right superior temporal pole, 
caudate, right thalamus, and cerebellum. 
WB: whole brain; ROI: region of interest; pACC: pregenual anterior cingulate cortex; ACC: anterior cingulate cortex; DLPFC: dorsolateral prefrontal 
cortex; Ins: insule 
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Table 3: Resting state analysis 
Study Diagnosis Comorbidities Connectivity 
 
Scanner 
(T) 
N. 
Cases/controls 
Mean age  
Analyses Results in major depression  
Anand et 
al., 2005 
DSM IV Excluded Seed analysis 1.5T  12/11 
30 years 
Amygdale, 
pACC, 
mTHA, PS, 
(ROI) 
 connectivity between ACC and left 
and right mTHA following treatment 
with Sertraline for 6 weeks. 
Lai and 
Wu, 2012 
DSM IV Panic disorder Regional 
homogeneity 
3T  15/15 
36 
WB  regional homogeneity in right 
superior frontal cortex, right mFC and 
 in the right superior temporal cortex 
after 6 weeks treatment with 
Duloxetine. 
Li et al., 
2013 
DSM IV Excluded Independent 
component 
analysis 
1.5T  24/29 
32 
Default 
mode 
network 
 connectivity in a posterior network 
comprising the bilateral precuneus and 
in an anterior network which included 
the medial prefrontal cortex. Following 
12-week treatment with Paroxetine, 
Citalopram, Venlafaxine or Duloxetine 
only connectivity in the posterior 
network normalised in 16 patients 
scanned twice. 
Fu et al., 
2015 
DSM IV Excluded Independent 
component 
analysis 
3T  32/25 
40 
Default 
mode 
network 
Eyes closed 
 connectivity in the default mode 
network between right DLPFC, right 
superior frontal premotor cortex and 
left inferior frontal gyrus after 12 
weeks of treatment with Duloxetine. 
Wang et 
al., 2015 
DSM IV Excluded Graph theory 
functional 
connectivity 
strength 
3T  20/20 
35 
Seed-based 
connectivity 
analyses 
 functional connectivity strength in 
the bilateral DMPFC following 
treatment with Escitalopram after 8 
weeks.  The bilateral hippocampus 
followed an inverse pattern. 
Cheng et 
al., 2017 
DSM IV Excluded Fractional 
amplitude of 
low-
frequency 
fluctuation  
1.5T  74/74 
29 
WB  signal following acute (5H) and sub-
chronic (4W and 8W) Escitalopram 
treatment administration in the 
bilateral post-central gyrus and left 
superior temporal gyrus and  in a vast 
area of the prefrontal cortex 
incorporating DMPFC and DLPFC. 
WB: whole brain; ROI: region of interest; ACC: anterior cingulate cortex; mTHA: medial thalamus; DLPFC: dorsolateral prefrontal cortex; DMPFC: 
dorsomedial prefrontal cortex; PCC: posterior cingulate cortex, mFC: medial frontal cortex; 
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Highlights 
 This work summarises the literature of longitudinal functional magnetic resonance 
imaging studies in major depression to identify brain regions where aberrant neural 
activity normalises after clinical response following treatment with pharmacological 
compounds with known antidepressant properties.  
 Hyperactivity in regions such as the amygdala and the ventral components of the 
anterior cingulate cortex were some of the most replicated findings of functional MRI 
studies in major depression and normalisation of aberrant activity one of the best 
predictive biomarkers of treatment response.   
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